Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
TP53 wild-type
i
Other names:
TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
7157
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive: A2 - Guideline
alemtuzumab
Sensitive
:
A2
alemtuzumab
Sensitive: A2 - Guideline
alemtuzumab
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
chlorambucil
Sensitive: A2 - Guideline
chlorambucil
Sensitive
:
A2
chlorambucil
Sensitive: A2 - Guideline
chlorambucil
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
venetoclax + obinutuzumab
Sensitive
:
A2
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
venetoclax + obinutuzumab
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
CD20 inhibitor
Sensitive: A2 - Guideline
CD20 inhibitor
Sensitive
:
A2
CD20 inhibitor
Sensitive: A2 - Guideline
CD20 inhibitor
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
obinutuzumab + acalabrutinib
Sensitive
:
A2
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
obinutuzumab + acalabrutinib
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
ibrutinib + obinutuzumab
Sensitive: A2 - Guideline
ibrutinib + obinutuzumab
Sensitive
:
A2
ibrutinib + obinutuzumab
Sensitive: A2 - Guideline
ibrutinib + obinutuzumab
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
ibrutinib + rituximab
Sensitive: A2 - Guideline
ibrutinib + rituximab
Sensitive
:
A2
ibrutinib + rituximab
Sensitive: A2 - Guideline
ibrutinib + rituximab
Sensitive
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.